Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for High-risk neuroblastoma, drawn from the whole corpus: 14 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
About half of children relapse and relapsed disease is rarely cured.
Nothing recorded yet.
Also on OnCo: Treatment journeys · Survivorship planner.
MYCN has no direct inhibitor; eflornithine and lorlatinib act around it.
Cisplatin hearing loss, infertility and second cancers in survivors of the most intensive regimen in paediatric oncology.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 22 changes by month →When this page itself was last checked or edited.
Maintenance to reduce relapse risk in high-risk neuroblastoma after ≥PR to prior therapy including anti-GD2
No patient had unacceptable toxicity and none was a feasibility failure over the first five induction cycles with dinutuximab and GM-CSF added.
ORR 63%, CR 33%; 3-year OS 60%.
EFS HR 0.
A milestone in how this cancer is treated.